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Objective: The purpose of this study is to determine primarily the occurrence of left ventricular 
hypertrophy (LVH) in normotensive Trinidadians.
Design and methods: Enrolment into the study required participants to have normal blood 
pressure (#140/90) using the JNC 7 (The Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) classification, free 
of type 2 diabetes, as well as no existing LVH. Upon entry into the study, participants were first 
screened for LVH using a standard 12-lead electrocardiogram (ECG), using the Sokolow–Lyon 
index and the Cornell index. ECHO was used to confirm or refute the diagnosis of LVH.
Results: A total of 209 patients met the criteria for entry into the study. Of these, 63.6% had 
LVH using Cornell criteria and 68.2% using LVH by Sokolow–Lyon criteria. Subsequently, 
ECHO confirmed the diagnosis in 2.9% using American Society of Echocardiography criteria 
and 1.5% using World Health Organization criteria. Thus the estimated prevalence of LVH in 
normotensive individuals was approximately 3%.
Conclusion: The estimated prevalence of LVH in normotensive individuals appears to be 
relatively high if an ECG is the single investigation performed, which is common in our setting 
and may also be common in the developing world. However, using ECHO, the prevalence of 
LVH approaches a value similarly reported in the literature. Therefore, these findings raise two 
important issues: 1) the use of criteria such as the Cornell and Sokolow–Lyon voltage criteria 
established in the developed world from populations of vastly different ethnic backgrounds 
may not be widely applicable, and 2) all individuals suspected of having LVH should have an 
ECHO.
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Introduction
Left ventricular hypertrophy (LVH) occurs when left ventricular mass (LVM) exceeds 
the normal range, and it is a substantial independent predictor of cardiovascular 
  morbidity and mortality.1 LVH can be physiological, occurring in athletes or adaptive 
to systemic hypertension, or aortic valve stenosis.2–4 It may occur in infiltrative systemic 
disease such as amyloidosis or lysosomal storage disease (Aderson–Fabry disease)5 or 
as familial hypertrophic cardiomyopathy. In a small proportion of individuals, LVH 
may occur without hypertension or any other recognized underlying pathology.6,7 We 
refer to this subset of LVH as LVH in normotensive individuals.
LVH is a silent epidemic in North America, affecting more than 16% of the US 
adult population, and it is noted to be a progressive disorder.8 It increases   morbidity by 
increasing the risk of arrhythmias, ischemic heart disease, and myocardial   infarction.9 Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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In addition, LVH is independently associated with an 
increased risk of stroke, sudden cardiac death, and heart 
failure.2,3 Carluccio et al reported that in 111 patients with 
acute myocardial infarction, 45% with LVH developed 
further cardiac complications compared with 6.9% without 
LVH.10 In 1995, Liao et al reported that patients with LVH 
and normal coronaries had a mortality of 16.1%.11 However, 
among those with single vessel disease and no LVH, the 
mortality was 10.9%.11 LVH more than doubled the risk of 
a fatal event, and for every 100 deaths, LVH independently 
accounted for 37.11 The presence of LVH was associated 
with a mortality risk of 50% greater than coronary artery 
disease.10 Scuteri et al in 2009 noted that increase in LVM is 
associated with noncardiac complications such as cognitive 
decline and dementia in the elderly independent of elevated 
blood pressure (BP).12
In Trinidad and Tobago, cardiovascular disease is the 
leading cause of death, with hypertension being a signifi-
cant contributor.13 In 2001, hypertension alone, without any 
other comorbidity accounted for 4.2% of total all-cause 
mortality.13
Apart from hypertension, the Framingham Heart Study 
in 1990 identified age, body mass index, and both visceral 
and free fat mass, as factors contributing to LVH.14 The 
prevalence of LVH increases with age, affecting more than 
one-third of individuals over the age of 70.8 Patrick et al 
reported in 1995 that 27.4% of men and 9.7% of women 
in Tobago had LVH. He further showed that mean LVM 
increased progressively across 10-year age groups between 
25 and 64 years in both sexes.15 In 1994, de Simone and 
  colleagues identified in a New York setting that 14% of obese 
normotensive subjects had LVM above the upper limit as 
compared with 4% with normal weight.16
Diabetes and ethnicity have also been found to be asso-
ciated with LVH. In 1998, Sato et al reported an increase 
LVM in normotensive Type 1 diabetic patients.17 In 2003, 
Taskiran et al showed that in normotensive type 1 diabetic 
patients with autonomic neuropathy, LVM index (LVMI) 
was higher than healthy subjects.18
As far back as 1986, Radice et al demonstrated that 
normotensive adolescents with a family history of hyperten-
sion had an LVM significantly greater than normotensive 
adolescents with normotensive parents.19 In 1990, Alli and 
colleagues further demonstrated that 12.2% of normo-
tensive adolescents who had a parent with hypertension, 
developed LVH as compared with 2% whose parents were 
normotensive.20
The purpose of this study is to determine primarily the 
prevalence of LVH in normotensive Trinidadians as well as 
to measure the proportion of various predisposing factors 
to cardiovascular disease among healthy individuals in the 
community.
Method
We used a cross-sectional study design. Participants were 
recruited from four Primary Health Care Facilities in 
  North-East Trinidad. Enrolment into the study required par-
ticipants to have normal BP (#140/90) at the time of entry, 
using the JNC 7 (The Seventh Report of the Joint National 
  Committee on Prevention, Detection, Evaluation, and Treat-
ment of High Blood Pressure) guidelines21 and free from 
type 2 diabetes World Health Organization (WHO) criteria. 
In addition participants were required to have no previous 
history of a diagnosis of hypertension including hypertension 
in pregnancy, no current or previous history of being treated 
for hypertension, and age . 16 years. Participants who satis-
fied these criteria were further screened to exclude existing 
hypertension defined as a systolic BP $ 140 mmHg and a 
diastolic BP $ 90 mmHg, JNC 7 classification.21 Participants 
were also screened for pre-existing LVH due to any underlying 
pathological conditions such as diabetes, aortic stenosis, or 
alcoholic cardiomyopathy, by enquire and clinical records.
Thus, only normotensive nondiabetic patients with no prior 
medical evidence of LVH were entered into the study.
Data were collected by asking the participants to complete 
a self administered pretested structured questionnaire con-
taining 19 items. Clinical data collected include measurement 
of BP at the time of entry into the study. BP was measured 
initially in the sitting position using a mercury column sphyg-
momanometer using a standard technique: on the left arm 
of each subject using a cuff of appropriate size at the level 
of the heart. The cuff pressure was inflated 30 mmHg above 
the level of which the radial pulse disappeared and deflated 
slowly at a rate of 2 mmHg/second and the reading recorded 
to the nearest 2 mmHg. The first (appearance) and the fifth 
(disappearance) Korotkoff sounds were recorded as indica-
tive of the systolic BP and the diastolic BP respectively. In 
cases where the two readings differed by over 10 mmHg, a third 
reading was made and the three readings averaged.22
In addition, height (m) and weight (kg) were measured 
from which body mass index (BMI) (kg m−2) was   calculated. 
Participants were classified as either overweight (BMI 
25.0–29.9 kg m−2) or obese ($30 kg m−2) according to WHO 
criteria.23Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Participants were then screened for LVH using a   standard 
12-lead electrocardiogram (ECG). Recordings were made 
with subjects lying flat in the supine position. The ECG 
machine was calibrated and tested prior to recording the 
ECG as outlined by the machine manual. The ECG coding 
quality assurance methods as outlined by the MONICA 
study was adopted for use in the study.24 As such, each ECG 
was coded by two independent coders, each unaware of the 
results of the other. Further, the codes established by the 
two coders separately were compared. However, if only one 
coder was available, the ECGs were subsequently re-coded 
after an interval of usually 24–48 hours. In the case of a 
discrepancy between the two coders, a third senior coder re-
coded the ECG without knowing the codes of the two other 
coders. After having established his/her own code, the three 
  coders discussed the findings and made a final decision.24 
We used both the Sokolow–Lyon index25 [S in V1 + R in V5 
or V6 (whichever is larger) $35 mm] and the Cornell index26 
[R in AVL + S in V3, .24 mm for males and .20 mm for 
females], to establish LVH by ECG. Participants who had 
elevated S and R waves due to arrhythmias, ventricular 
ectopic beats, ventricular extrasystole, myocardial isch-
emia, acute myocardial infarction, left bundle branch block, 
acute pericarditis, hyperkalemia, pulmonary embolism, and 
digoxin toxicity were not considered as having pure LVH 
and were therefore eliminated from the analysis.
M-mode echocardiograms were recorded on strip-chart 
paper with the subject in a partial left decubitus position. 
M-mode recordings were made with the ultrasound beam at or 
just below the tips of the mitral valve leaflets. We used conven-
tional LVM calculations based on linear measurements derived 
from two-dimensional targeted M-mode   echocardiography.27 
Strip-chart tracings were coded and interpreted by two blinded 
observers. Measurements of septal and posterior wall thick-
ness and left ventricular chamber dimensions were obtained 
according to the guidelines of the American Society of 
Echocardiography (ASE). We used the ASE recommended 
formula28 for estimating LVM from left ventricle linear dimen-
sions (validated with necropsy r = 0.90, P , 0.001)27 which 
is based on modelling the left ventricle as a prolate ellipse of 
revolution. The formula used is LVM = 0.8 × (1.04 [(LVIDd + 
PWTd + SWTd)3 – (LVIDd)3]) + 0.6 g, where LVID is the 
left ventricular internal dimension, and PWTd and SWTd are 
posterior wall thickness at end diastole and septal wall thick-
ness at end diastole, respectively.28 Calculation of relative wall 
thickness (RWT) by the formula (2 × PWTd)/LVIDd permits 
categorization of an increase in LVM as either concentric 
(RWT $ 0.42) or eccentric (RWT # 0.42) hypertrophy and 
allows identification of concentric remodelling (normal LVM 
with increased RWT).28
Using the recommendations of the ASE,26 LVH was 
defined as (LVM/BSA),28 where BSA is body surface area 
calculated using the following formula: BSA = ((Height(m)/
weight(kg)) × 3600)0.5. LVMI was measured by echocar-
diography normalized for body height to the allometric 
power of 2.7 (LVMI = LVM/height2.7). LVH was defined as 
a LVMI . 50 g/m2.7 for men and .47 g/m2.7 for women.28,29,31 
In addition, the LVM/BSA ratio was calculated as defined 
by the ASE, which is considered a more accurate way of 
normalizing LVM to the individual’s BSA, with LVH defined 
as .90 gm−2 for women and .114 gm−3 for men.28
Due to constraints of availability and cost, echocar-
diography was restricted to approximately 64% of subjects 
who had LVH as defined by both the Sokolow–Lyon’s and 
Cornell criteria.
Data were analyzed using SPSS version 16. Ethical 
approval for this study was obtained from The Ethics Com-
mittee of The University of The West Indies.
Results
A total of 224 patients were recruited for the study. In order 
to ensure that all patients who entered the study did not have 
hypertension BP was assessed at the time of entry into the 
study. Consequently, 15 patients met the criteria for hyperten-
sion for the first time (mean systolic BP [MSBP] = 161 ± 17, 
mean diastolic BP [MDBP] = 97 ± 17 mmHg, and mean arte-
rial pressures [MAP] ranging from 111 to 133.3 mmHg). In 
other words, while these patients gave no previous history of 
hypertension or were not receiving antihypertensive medica-
tions, BP at the time of entry into the study was elevated. 
Several factors may have contributed to this finding includ-
ing white coat hypertension, unrecognized hypertension, or 
the use of drugs. In fact, four patients admitted to the use 
of cigarettes, five to the use of alcohol, three cocaine, and 
one the use of marijuana, a total of 14 of the 15 patients. In 
addition, seven reported a family history of high BP. Conse-
quently, they were all eliminated from the analysis.
Of the 209 participants who were eligible for analysis, 
there were more females (124, 59.3%) than males 85 (40.7%), 
and the mean age of females (36, SD ± 13.8 years) was 
marginally higher than males (34, SD ± 13.5 years), a detail 
of the characteristics of the sample are listed in Table 1. The 
  proportion of LVH found based upon the four criteria used, two 
for ECG and two for echocardiogram are listed in Table 2.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 1 characteristics of study sample
Sample characteristic n (%) Sample characteristic n (%)
gender smoking
  Male 85 (40.7%)   current smoker 19 (9.1%)
  Female 124 (59.3%)   nonsmoker 130 (62.2%)
Total 209 (100%)   Previous smoker 60 (28.7%)
Total 209 (100%)
Age range Male Female Alcohol consumption
  17–26 33 (15.8%) 40 (19.1%)   Yes 106 (50.7%)
  27–36 15 (7.8%) 25 (11.9%)   no 103 (49.3%)
  37–46 20 (9.5%) 31 (14.8%) Total 209 (100%)
  47–56 11 (5.2%) 17 (8.0%) exercise
  57–66 5 (2.4%) 7 (3.3%)   never 58 (27.8%)
  .66 1 (0.5%) 4 (1.9%)   ,3 days/month 39 (18.7%)
Total 85 (40.7%) 124 (59.3%)   Once per week 34 (16.3%)
ethnicity   3 × per week 38 (18.2%)
  seA 39 (18.7%) 50 (23.9%)   .3 × per week 40 (19.1%)
  Africans 37 (17.7%) 63 (30.1%) Total 209 (100%)
  Other 09 (4.3%) 11 (5.3%) BMi
Total 85 (40.7%) 124 (59.3%)   ,18.5 14 (6.7%)
  18–24.9 82 (39.5%)
  25–29.9 70 (33.3%)
  30–35 38 (18.1%)
  .35 5 (2.4%)
Total 209 (100%)
Abbreviations: seA, south east Asian; BMi, body mass index.
Table  2  The  proportion  of  LVH  found  using  ecg  and 
echocardiographic criteria
Criteria Male Female Total
ECG
sokolow–Lyon 17 (20.0%) 5 (4.0%) 22 (10.5%)
cornel 6 (7.0%) 5 (4.0%) 11 (5.3%)
Echocardiogram
Ase  3 (20.0%) 1 (6.7%) 4 (26.7%) 
WHO 1 (6.7%) 1 (6.7%) 2 (13.3%)
Abbreviations:  Ase,  American  society  of  echocardiography;  ecg,  electro-
cardiogram; LVH, left ventricular hypertrophy; WHO, World Health Organization.
Using the Sokolow–Lyon criteria, 27 participants had 
LVH. However, 5 of the 27 participants had ST segment eleva-
tion in addition to LVH and were consequently eliminated 
from   analysis. Hence, only 22 (10.5%) patients had LVH 
using Sokolow–Lyon criteria (95% confidence interval [CI], 
10.1–10.9), with a higher proportion among males (17/85, 
20.0%) than females (5/124, 4.0%). The range of Sokolow–Lyon 
scores were 38.3–52.9 mm, with a mean of 40.3 (SD ± 4.7) mm. 
Using Pearson’s correlation method, we attempted to correlate 
Sokolow–Lyon’s scores with LVMI and found a correlation 
coefficient of 0.32 (P = 0.07), and with LVM/BSA, found a 
correlation coefficient of 0.37 (P = 0.045).
Similarly, using Cornell Voltage criteria, 11 (5.26%), 
(95% CI, 4.98–5.54) patients had LVH, again with a higher 
proportion in males (6/85, 7.0%) than females (5/124, 4.0%). 
The range for Cornell criteria for men was 29–40 mm with 
a mean of 32.5 (SD ± 4.03) mm, whereas for women was 
21–42 mm with a mean of 26 (SD ± 8.3). Using Pearson’s cor-
relation method, we attempted to correlate Cornell scores with 
LVMI and found a correlation coefficient of 0.53 (P = 0.047), 
and with LVM/BSA, found a correlation   coefficient of 0.62 
(P = 0.021).
Of the individuals who tested positive by the Sokolow–
Lyon criteria, 15/22 (68.2%) were randomly chosen for 
confirmatory echocardiograms of whom 4/15 (26.7%) tested 
positive for LVH using the ASE criteria and 2/15 (13.4%) 
tested positive for LVH using the WHO criteria.
Extrapolating these results to all 22 subjects with LVH 
using ASE criteria, the estimated proportion of LVH in 
normotensive individuals is 2.9% (95% CI, 2.77–3.23). 
However, using WHO guidelines the estimated proportion 
of confirmed LVH was 1.5% (95% CI, 1.34–1.66).
Among individuals who tested positive using the Cornell 
voltage criteria, 7/11 (63.6%) were randomly chosen for 
confirmatory echocardiograms, of whom 4/7 (57.1%) tested 
positive for LVH using the ASE criteria and 2/7 (28.6%) 
tested positive for LVH using the WHO criteria.
Extrapolating these results to all 11 subjects with LVH 
using ASE criteria, the estimated proportion of LVH in Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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normotensive individuals is 2.9% (95% CI, 2.77–3.23). 
However, using WHO guidelines, the estimated prevalence 
is 1.5% (95% CI, 1.34–1.66).
Discussion
The main finding of this study was an estimated proportion 
of LVH in normotensive individuals of 2.9%. Patrick and col-
leagues reported in 1995 a proportion of 27.4% in men and 
9.7% in women using electrocardiographic (Sokolow–Lyon) 
criteria only.15 Our findings appear markedly lower, which 
may be attributed to more rigorous evaluation of LVH, ie, the 
use of echocardiograms as well as the use of other criteria 
apart from the Sokolow–Lyon criteria. In addition, these 
values were reported among participants with both diabetes 
and hypertension. A review of the literature revealed two 
other studies of LVH in patients without hypertension or any 
pathological conditions associated with LVH: the first was 
reported by Antoniucci et al, in 1997, who reported a preva-
lence of 2.7%–3.2% adjusted for height, age, BMI, and BSA.6 
The other in 2007, by Ruiz-Nodar et al who showed that in a 
group of elderly normotensive subjects with a mean age of 
72, the prevalence of LVH ranged from 30% by Cornell–Penn 
criteria to 14% by Devereaux criteria.31
Another important finding was although 60% of patients 
had increased LVM by echocardiographic evaluation when 
normalized for BSA according to ASE specifications and 
height according to WHO specifications, only four patients 
had LVH. Of these four participants, 20% (3/15) were over-
weight as opposed to 6.7% (1/15) who had a normal weight. 
Similarly de Simone et al reported in 1994 that 14% of 
normotensive individuals who were overweight had LVH, 
compared with 5% who were normal weight.16 Our find-
ings raise an issue for further investigation in normotensive 
patients: will reduction in BP below currently recommended 
targets reduce LVH.
The traditional Sokolow–Lyon voltage and the Minnesota 
code high QRS amplitude (WHO Monica study) are prone to 
errors by extra cardiac factors such as body weight, obesity, 
breast tissue, pulmonary conditions, chest size and shape in 
relation to cardiac size, QRS axis and ventricular conduction 
problems. Cornell voltage criterion is less vulnerable to 
such factors.33 In our setting based on a higher Pearson’s 
correlation (Sokolow–Lyon r = 0.366, Cornell r = 0.618), 
we provide further support for this position. Sokolow and 
Lyon introduced their LVH criterion in 1949.32 Many studies 
have shown the sensitivity of this criterion is low, and it is 
perplexing that the Sokolow–Lyon’s LVH criterion continues 
to be used in the clinical evaluation of patients, especially 
in the developing world with limited resources for more 
advanced evaluations. Rodrigues et al in 2008 showed the 
classic Sokolow–Lyon Rappaport and Cornell Voltage criteria 
showed a low performance in relation to LVH, as confirmed 
by ECHO,33 our results support these findings as only 4 out 
of the 15 participants with LVH by Sokolow–Lyons criteria 
had confirmed LVH by echocardiography.
Alli and colleagues in 1990 showed that 12.2% of nor-
motensive adolescents who had a parent with hypertension 
developed LVH.20 Our findings provide further evidence of a 
possible familial link between parental hypertension and the 
development of LVH, as 100% of participants with echocar-
diographic confirmation of LVH gave a family history of 
high BP.
A major limitation of the study was the use of two-
dimensional echocardiography, which is less accurate and 
has greater test–retest variability than newer methods such 
as cardiac magnetic resonance imaging or real-time three-
dimensional echocardiography, which are unavailable on 
the island. The number of confirmed participants with LVH 
by echocardiographic was small hence risk factor analyses 
could not be conducted. In addition the availability and cost 
of echocardiograms restricted the number of participants who 
could be further assessed.
We recommend further studies with larger sample sizes 
with the capacity for all participants to be evaluated further 
using echocardiography. Risk factors associated with LVH 
should also be assessed. LVH in normotensive individuals 
is an important subset of cardiac patients, as Brown et al34 
showed that individuals who were normotensive and had LVH 
had a greater risk of developing cardiac complications and 
as such should receive adequate follow up.
In conclusion, we provide evidence of the existence of 
LVH in normotensive individuals in Trinidad with a proportion 
of 2.9%. LVH appears to be relatively high if an ECG is the 
single investigation performed, which is common in our setting 
and may also be common in the developing world. However 
using echocardiography, the prevalence of LVH approaches a 
similar value as reported in the literature. Therefore our study 
confirms: 1) the use of the Cornell and Sokolow–Lyon voltage 
criteria established in the developed world from populations 
of vastly different ethnic backgrounds may not be widely 
applicable, and 2) all individuals suspected of having LVH 
should have a confirmatory echocardiogram as part of their 
management.
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